Corvus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Corvus Pharmaceuticals

03/11/2022 21:02

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 32 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 16 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 32 cents​.
    * The mean earnings estimate of analysts had risen by
about 31.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Corvus Pharmaceuticals Inc shares had risen by 5.5% this
quarter and lost 64.2% so far this year.
    * The company reported a quarterly loss of $14.83 million.
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $3.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.16          -0.32          Missed
 Jun. 30 2022      -0.18          -0.18          Met
 Mar. 31 2022      -0.15          -0.18          Missed
 Dec. 31 2021      -0.19          -0.20          Missed